FDA Recommends Use of Placebo Only in Certain Oncology Trials

Given the ethical challenges of using a placebo in randomized controlled clinical trials for therapies to treat hematologic malignancy and oncologic disease, the US Food and Drug Administration (FDA) recommends that a sponsor use a placebo-controlled design only in select circumstances, according to new draft guidance released Thursday.